- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00579813
Mechanisms Underlying Metabolic Syndrome in Obesity
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Obesity is the most common and powerful force for creating insulin resistance and metabolic syndrome, however, the molecular basis of this association is not well understood. In this proposal, three independently funded researchers-Philip Kern, MD a clinical investigator, and Charlotte Peterson, PhD and Robert McGehee, PhD, with significant experience in muscle and adipocyte biology, respectively-will formalize a collaborative effort as a natural extension of previous work and shared interests in the fields of obesity, insulin resistance, and tissue lipid accumulation. Our overall hypothesis is that insulin resistance in humans stems largely from ectopic accumulation of intramyocellular lipid (IMCL) during the development of obesity. Further, we hypothesize that excess IMCL accumulation is dependent on secretory proteins derived from a complex interplay between adipocytes and macrophages in adipose tissue. To test these hypotheses, we will examine the interactions among adipocytes, macrophages, and muscle cells isolated and cultured from subjects that are obese with insulin resistance and impaired glucose tolerance (IGT), and from some with Type 2 Diabetes. This study population has elevated IMCL and is at high risk for obesity complications, but avoids the pathophysiologic complications of glucotoxicity. These subjects will be compared to obese subjects with normal glucose tolerance (NGT).
Aim 1 will explore mechanisms that contribute to IMCL and elucidate its role in the development of IGT. Cultured muscle cells will be used to determine whether obese subjects with IGT versus NGT demonstrate intrinsic differences in muscle gene expression and metabolic activity under differing extracellular fatty acid concentrations. Lipid accumulation and oxidation, and insulin-mediated glycogen synthesis and signaling will be assessed.
Aim 2 will determine if the IMCL accumulation is dependent on adipose tissue secretory proteins. We will use co-cultures of adipocytes, myoblasts, and adipose stromal vascular cells to examine IMCL and the development of insulin resistance.
Aim 3 will determine whether the stromal fraction from IGT subjects promotes IMCL more effectively than that from NGT subjects in co-cultures with muscle cells. We will compare the stromal vascular fractions with regard to monocyte/macrophage accumulation and cytokine expression.
Aim 4 will determine if improved glucose tolerance in response to a 10-week treatment with pioglitazone results in decreased IMCL and identify cellular mechanisms involved. Co-culture studies will also be used with muscle and stromal cells, before and after pioglitazone treatment. These experiments will provide mechanistic insight into the link between obesity and muscle function leading to metabolic syndrome.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72205
- University of Arkansas for Medical Sciences
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40536
- University of Kentucky
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- 18-65 years of age
- BMI 28+
- diabetes, impaired glucose tolerance or normal glucose tolerance
Exclusion Criteria:
- AST >2x normal
- congestive heart failure
- history of coronary artery disease
- chronic renal insufficiency (creatinine > 1.4mg/dl)
- use of gemfibrozil, ACE inhibitors, and angiotensin receptor II blockers, or anticoagulants
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Inget ingripande: 1
Baseline studies (OGTT, DXA, RMR, FSIGT, and biopsies) on normal control subjects.
Oral glucose tolerance tests, body composition assessment, resting metabolic rate, insulin sensitivity measurement with the frequently sampled method and Minimal Model.
These studies will establish baseline data in lean subjects on adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition.
There is no intervention.
|
|
Aktiv komparator: 2
Baseline studies (OGTT, DXA, RMR, FSIGT, biopsies), then 10 weeks treatment on Pioglitazone.
Baseline tests are repeated at the end of medication treatment.
All of the studies described in arm 1 are repeated after treatment.
The subjects in this group have impaired glucose tolerance.
After the measurement of adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition, subjects are treated with pioglitazone, working up to 45 mg/day, for 10 weeks.
After this time, adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition are repeated.
|
Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change in Insulin Sensitivity Using FSIGT
Tidsram: Baseline and 10 weeks
|
The frequently sampled intravenous glucose tolerance test (FSIGT) involves the injection of IV glucose and the frequent measurement of glucose and insulin.
|
Baseline and 10 weeks
|
Effects of Pioglitazone on Changes in BMI
Tidsram: Baseline and 10 weeks
|
Body Mass Index (BMI) is measured at baseline, in lean and obese subjects, and after pioglitazone in obese subjects
|
Baseline and 10 weeks
|
Changes in Muscle Lipid After Pioglitazone
Tidsram: At baseline and 10 weeks
|
Muscle lipid following biopsy using oil red-O staining.
|
At baseline and 10 weeks
|
Changes in Fat Inflammation Following Pioglitazone
Tidsram: Baseline and 10 weeks
|
macrophages in fat at baseline, in lean and obese participants, and obese after pioglitazone (in obese)
|
Baseline and 10 weeks
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Philip Kern, MD, University of Kentucky
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 32677
- R01DK071277 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Metaboliskt syndrom
-
Grand Valley State UniversityAnmälan via inbjudanMetabolic Associated-dysfunction Steatotic Lever Disease (MASLD) | Metabolic Associated-dysfunction Steatohepatit (MASH)Förenta staterna
-
Scripps Whittier Diabetes InstituteAvslutadCardio-metabolic Care-Team Intervention (CMC-TI)
-
Shanghai General Hospital, Shanghai Jiao Tong University...Har inte rekryterat ännuPrediabetes | Kontinuerlig glukosövervakning | Metabolic Management Center
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AvslutadTidigare behandlat myelodysplastiskt syndrom | Myelodysplastiskt syndrom | Terapierelaterat myelodysplastiskt syndrom | Sekundärt myelodysplastiskt syndrom | Refraktärt högrisk myelodysplastiskt syndromFörenta staterna
-
National Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
Institut de Recherches Internationales ServierServier Bio-Innovation LLCHar inte rekryterat ännuMyelodysplastiska syndrom (MDS) | Hypometylerande medel (HMA) Naiva myelodysplastiska syndrom (MDS)
-
SCRI Development Innovations, LLCNovartis PharmaceuticalsAvslutadMyelodysplastiska syndrom (MDS)Förenta staterna
-
PersImmune, IncUniversity of California, San DiegoOkänd
-
TJ Biopharma Co., Ltd.Rekrytering
Kliniska prövningar på Pioglitazone
-
Dong-A ST Co., Ltd.AvslutadDiabetes typ 2Korea, Republiken av
-
University at BuffaloTakeda Pharmaceuticals North America, Inc.Avslutad
-
Emory UniversityAvslutadDiabetisk ketoacidos | Diabetes med benägenhet för ketos | Svår hyperglykemiFörenta staterna
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceHar inte rekryterat ännuANCA associerad vaskulit | Snabbt progressiv glomerulonefrit | Crescentisk glomerulonefrit
-
West Virginia UniversityRekryteringBröstcancer | MuskeltrötthetFörenta staterna
-
University of Texas Southwestern Medical CenterRekryteringNefrolitiasis, urinsyraFörenta staterna
-
GlaxoSmithKlineAvslutadIcke-insulinberoende diabetes mellitusFörenta staterna
-
TakedaZinfandel Pharmaceuticals Inc.AvslutadLindrig kognitiv funktionsnedsättning på grund av Alzheimers sjukdomFörenta staterna, Tyskland, Schweiz, Storbritannien, Australien
-
Torrent Pharmaceuticals LimitedAvslutad
-
Brooke Army Medical CenterThe Geneva FoundationAvslutadKronisk hepatit CFörenta staterna